Swiss oncology powerhouse Roche (ROG: SIX) has reported positive results from the Phase III ALINA study of Alecensa (alectinib).
Compared with chemotherapy, the product demonstrated a superior clinical effect as measured by disease-free survival (DFS), the primary endpoint in the trial.
The results, which were reached at a prespecified interim analysis, show the potential of Alecensa as adjuvant therapy in certain people with completely resected non-small cell lung cancer (NSCLC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze